Texas-based Scorpius Biomanufacturing expanded its leadership team to include a VP of manufacturing operations, the company announced late last month.
The contract development and manufacturing organization named Matthew LeClair for the role. LeClair brings over 30 years of experience ranging from research and development to commercial manufacturing. He will oversee all manufacturing operations at Scorpius’ first facility in San Antonio which has available capacity for clinical-scale mammalian and microbial manufacturing, according to a June 29 release.
LeClair previously served as SVP and site head for San Diego operations at Abzena. Before which he worked at Takeda, where he led biologics facilities in Singapore and the U.S.
“It’s important to have manufacturing leaders be committed to quality and compliance, and Matthew is extremely committed,” said Scorpius’ VP of Quality and Regulatory Affairs Joe Payne in a statement. “He fits seamlessly at Scorpius because he does not take shortcuts. He’s had an immediate impact on the organization.”
LeClair joins Scorpius as the CDMO eyes growth, with plans to construct a $650 million commercial-scale biomanufacturing facility in Manhattan, Kansas, less than a year after opening its first facility. Scorpius said LeClair will be closely involved in the project.
The Kansas site will allow clients to remain with Scorpius throughout the product life cycle, starting their projects using the immediate capacity at the San Antonio location, the company said.
“This is a once-in-a-career- opportunity to build a premier biomanufacturing company from the ground up, and to build it the right way,” LeClair said in a statement.
